Drugs / AMT-162
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06100276 | Aug 2024 → Sep 2026 overdue | amyotrophic lateral sclerosis | UniQure Biopharma B.V. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-01-30 | UniQure Biopharma B.V. | Results uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS gcs-web.com ↗
The IDMC’s review identified no significant safety concerns and recommended proceeding with enrollment in the second cohort. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-01-30 | UniQure Biopharma B.V. | uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS gcs-web.com ↗ |
| 2024-10-15 | UniQure Biopharma B.V. | uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment of SOD1-ALS gcs-web.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMT-162 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06100276 ↗ |
| Action | Inhibit | “it will silence expression of mutant cytosolic SOD1” NCT06100276 ↗ |
| Route | Intrathecal | “delivered via an intrathecal (IT) infusion” NCT06100276 ↗ |
| Target | SOD1 | “artificial miRNA targeting the SOD1 gene” NCT06100276 ↗ |